Peptide-based vaccine

Phase 1Vaccine

Peptide-based vaccine is one of 8 small molecule programs targeting Myeloproliferative Neoplasm. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myeloproliferative NeoplasmRecruiting

Myeloproliferative NeoplasmPhase 1

Recruiting

Competition

Competitive Landscape

7 competitors in Myeloproliferative Neoplasm

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 2

2 2

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

2 3

Jakafi

Incyte

Phase 1

1 4

Celebrex

PPhiladelphia Eye Associates

Phase 1

1 5

Vonjo

SSobi, Inc.

Phase 1

1 6

Navitoclax

AbbVie

Phase 1

1 7

Poly ICLC

CCelldex Therapeutics

Phase 1

1 8

Peptide-based vaccine

MMarina Kremyanskaya

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Myeloproliferative Neoplasm

NCT05025488

Clinical

Trials by Indication[1]

Myeloproliferative Neoplasm1 trial

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

Recruiting·MMarina Kremyanskaya·Phase 1·NCT05025488·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Peptide-based vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peptide-based vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peptide-based vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Marina Kremyanskaya company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: MMarina Kremyanskaya

Peptide-based vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Myeloproliferative Neoplasm1 trial

References

Drug Info

Quick Facts

Related News